# Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis

> **NCT07525427** · PHASE2 · RECRUITING · sponsor: **Gates Medical Research Institute** · enrollment: 150 (estimated)

## Conditions studied

- Drug Susceptible Pulmonary Tuberculosis

## Interventions

- **DRUG:** Bedaquiline, pretomanid and TBD09
- **DRUG:** Bedaquiline, pretomanid and TBD09
- **DRUG:** Bedaquiline, pretomanid and TBD09
- **DRUG:** Bedaquiline, pretomanid and TBD09
- **DRUG:** Bedaquiline, pretomanid and linezolid

## Key facts

- **NCT ID:** NCT07525427
- **Lead sponsor:** Gates Medical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2026-11-05
- **Final completion:** 2026-11-05
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- IQVIA RDS Inc.

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07525427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07525427, "Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07525427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*